US 11,834,686 B2
Engineered target specific base editors
Friedrich Fauser, Richmond, CA (US); Jeffrey C. Miller, Richmond, CA (US); and Edward Rebar, Richmond, CA (US)
Assigned to Sangamo Therapeutics, Inc., Brisbane, CA (US)
Filed by Sangamo Therapeutics, Inc., Richmond, CA (US)
Filed on Aug. 20, 2019, as Appl. No. 16/545,363.
Claims priority of provisional application 62/867,565, filed on Jun. 27, 2019.
Claims priority of provisional application 62/817,153, filed on Mar. 12, 2019.
Claims priority of provisional application 62/753,696, filed on Oct. 31, 2018.
Claims priority of provisional application 62/721,903, filed on Aug. 23, 2018.
Prior Publication US 2020/0063114 A1, Feb. 27, 2020
Int. Cl. C12N 9/22 (2006.01); C12N 9/78 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01)
CPC C12N 9/22 (2013.01) [C12N 9/78 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); C12Y 305/04001 (2013.01); C12Y 305/04002 (2013.01); C12N 2310/20 (2017.05); C12N 2310/3181 (2013.01); C12N 2310/323 (2013.01); C12N 2310/3231 (2013.01); C12N 2800/80 (2013.01)] 8 Claims
 
1. One or more expression vectors for expressing a system for editing an adenine or cytosine base in DNA, the system comprising:
a first fusion protein comprising a first inactive domain of an adenosine or cytidine deaminase and a first zinc finger protein (ZFP) DNA-binding domain,
a second fusion protein comprising a second inactive domain of the deaminase, a second ZFP DNA-binding domain, and a catalytically active or inactive nickase domain, and
a third fusion protein comprising a catalytically inactive or active nickase domain and a third ZFP DNA-binding domain,
wherein the first and second inactive domains of the deaminase dimerize to form an active deaminase, and
wherein the second and third fusion proteins form an active nickase through dimerization of the catalytically active and inactive nickase domains.